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Abstract
Background. In a previous study, the levels of pain
reported by patients with “possible” vascular
dementia (VaD) were higher than those reported by
older individuals without dementia.
Objective. To examine experienced pain in patients
with “probable” VaD, confirmed by brain imaging.
Study Design. Observational, cross sectional.
Setting. Nursing home.
Methods. The participants were 20 nursing home
residents (14 females, 6 males) who met the NINDS-
AIREN criteria for “probable” VaD and 22 nursing
home residents with a normal mental status (18
females, 4 males). The patients were in a mild to
moderate stage of dementia. All of the participants
were suffering from arthritis/arthrosis or osteoporo-
sis. Global cognitive functioning was measured by
the Mini-Mental State Examination. Pain was
assessed by the Coloured Analogue Scale (CAS:
original and modified version) and the Faces Pain
Scale. The Geriatric Depression Scale and the
Symptom Checklist-90 were used to assess mood.
Results. The main finding was that, after controlling
for mood, the pain levels indicated by patients with
“probable” VaD (M = 102.32; standard deviation
[SD] = 53.42) were significantly higher than those
indicated by the control group (M = 59.17;
SD = 38.75), only according to the CAS modified
version (F[1,29]) = 5.62, P = 0.01, η2 = 0.16).
Conclusion. As VaD patients may experience
greater pain than controls, it is essential for pre-
scribers to be aware of the presence of this neuro-
pathology if these patients are to receive adequate
treatment.
Key Words: Pain Intensity; Pain Affect; Probable
Vascular Dementia; Pain Treatment; Central Neuro-
pathic Pain; White Matter Lesions
Introduction
Age is a risk factor for dementia [1]. More specifically, an
increase in life expectancy coincides with a higher preva-
lence of Alzheimer’s disease (AD) [2]. Age also enhances
the risk of pain [3], such as musculoskeletal pain [4]. As life
expectancy is expected to increase still further in the years
ahead [5], we argue that the number of dementia patients
suffering from pain will increase in the near future.
Most studies on pain in dementia focus on patients with
“dementia,” with no further specification of the diagnosis,
for example, AD, Lewy Body disease, vascular dementia
(VaD), combined AD and VaD, or frontotemporal dementia
(FTD). These are the most prevalent subtypes of demen-
tia [6,7]. The majority of clinical and experimental studies
on pain that did distinguish between subtypes of dementia
focused on patients with AD. In these studies, the pain
levels reported by AD patients were lower than those
reported by controls [8,9,10]. Indeed, a reduction in the
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use of analgesics was also found, particularly in the treat-
ment of chronic pain in AD patients [11]. It has been
suggested that in patients with AD, cortical atrophy
(including the hippocampus, for example) may cause a
decrease in experienced pain [12]. The hippocampus is
involved in the processing of pain, specifically its
motivational–affective and cognitive–evaluative aspects
[12]. In contrast, Cole and colleagues [13] found that brain
regions involved in pain processing show even higher
levels of activity in mild stage AD, which suggests that they
experience greater distress than those without dementia.
An increase in experienced pain in AD might also be due
to white matter lesions [14, 15]. White matter lesions may
cause an increase in experienced pain [16,17] by damag-
ing ascending pathways to the thalamus, for example,
such as the spinothalamic tract [18]. This is known as
central neuropathic pain, which can also affect stroke
patients [19]. However, white matter lesions are a neuro-
pathological hallmark of patients with VaD, much more so
than in AD. This may account for the fact that VaD patients
have the highest risk of suffering an increase in experi-
enced pain [12].
As far as the authors are aware, there has only been a
single study into the experience of clinical chronic pain in
patients with VaD [16]. The results of that study suggest
that VaD patients indicate higher levels of experienced
chronic pain. However, a serious limitation of this study
was that participants did not meet the diagnostic criteria
for “probable” VaD [20], the strictest diagnosis in living
patients. A diagnosis of “probable” VaD can only be made
if the presence of white matter lesions is confirmed by
brain imaging (CT or MRI) [20]. No such data were avail-
able in that study [16] as brain imaging is not a standard
procedure in nursing homes in the Netherlands. The most
feasible diagnosis in that study was “possible” VaD,
according to the criteria developed by Román and
coworkers [20].
The goal of the present study was, therefore, to take the
next logical step and refine the diagnosis. As a result, the
study only includes VaD patients who have had a CT scan
or MRI confirming a diagnosis of “probable” VaD [20].
Based on studies of poststroke pain [19] and on the study
of pain in patients with “possible” VaD [16], it was hypoth-
esized that pain levels (from chronic painful conditions
such as arthrosis/arthritis) indicated by patients with
“probable” VaD would exceed those indicated by older
individuals without dementia.
Methods
Subjects
The sample consisted of two groups of participants who
lived in three nursing homes belonging to one large
nursing home organization in the Netherlands. One group
consisted of 20 patients (14 females, 6 males) in a mild to
moderate stage of dementia (see Results, Global cognitive
functioning) who met the NINDS-AIREN criteria for “prob-
able” VaD [20]; the other consisted of 22 elderly individuals
without a cognitive impairment (18 females, 4 males).
Inclusion Criteria
First, the diagnosis of VaD was confirmed by the nursing
home physician and/or neurologist. Subsequently, to be
included in the study, our patients had to meet the follow-
ing NINDS-AIREN criteria for the diagnosis of “probable”
VaD [20]: 1) cognitive decline: an impairment in episodic
memory (word list learning) and in two or more other
cognitive domains; 2) a confirmation of the diagnosis of
VaD using a CT scan. More specifically, four patients were
found to have a lacunar infarction (basal ganglia, caudate
nucleus, 2× capsula interna), two patients had an intrace-
rebral hemorrhage (subarachnoid space), and five patients
had leuko-araiosis (periventricular). In the remaining five
patients, CT scans revealed only a single lesion (e.g.,
frontal, fronto-parietal). Concerning the remaining three
patients, no detailed information was available in the
medical records except for the diagnosis VaD; and 3)
executive dysfunction. In addition, the scores on recogni-
tion memory must be higher than the scores on active
retrieval after learning of a word list (Table 1); this finding
would further support the diagnosis of VaD [21]. For a
detailed description of the various neuropsychological
tests, see next section. A final inclusion criterion for both
groups was the presence of one chronic painful condition
(i.e., arthritis/arthrosis or osteoporosis). This information
was registered in the medical record and supported by the
treating nursing home physician specialist [22].
Exclusion Criteria
Individuals were excluded from participation if they had a
psychiatric history (e.g., depressive, bipolar disorder),
alcohol abuse, other neurodegenerative diseases (e.g., M.
Parkinson, a decline in consciousness, a stroke, and a
brain tumor). In addition, none of the patients had a diag-
nosis of AD or mixed dementia, which is indicative of
concurrent VaD and AD.
Education
Level of education was rated with an ordinal 7-point rating
scale [23]. Elementary school not finished: 1; elementary
school finished: 2; elementary school finished with addi-
tional education of less than 2 years: 3; lower level sec-
ondary school: 4; secondary school: 5; higher level
secondary school: 6; and preuniversity education: 7.
Comorbidity
All participants suffered from a chronic painful condition
(i.e., arthritis/arthrosis or osteoporosis). Other comorbi-
dities such as disorders of the circulatory tract (coronary
disease, heart disease, peripheral vascular disease), gas-
trointestinal tract, and urinary tract, lung disease (e.g.,
chronic obstructive pulmonary disease), endocrine dis-
eases (e.g., diabetes mellitus), and disorders of the
sensori-motor system were extracted from the medical
records.
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Depression and Anxiety
It is known that a close relationship exists between
depression, anxiety, and pain [24,25]. Therefore, the Geri-
atric Depression Scale (30 items) [26], Dutch version [27],
and the subscales depression (15 items) and anxiety (10
items) of the Symptom Checklist-90 [28], Dutch version
[29], were administered. To strive for data reduction, z
scores of the three scales were added to compose a
mood domain: Cronbach’s alpha: 0.85.
Medication
The prescription of the following medication was regis-
tered during the period spanning the two pain assess-
ments (see Procedure): acetaminophen, nonsteroidal anti-
inflammatory drugs (NSAIDs), and morphine. The
medication was prescribed on an “only-if-needed” basis.
Informed Consent
The participants and their legal representatives were
extensively informed about the aim and procedure of the
study. Subsequently, participants in the control group and
the patients were asked to participate and to fill in a written
informed consent. Concerning the patients, the legal rep-
resentatives were also asked for permission to include the
patient in the study and were requested to fill in a written
informed consent. The local medical ethical committee
approved the study.
Material and Procedure
Measures
Neuropsychological Assessment of VaD
Assessment of Global Cognitive Functioning. Global
cognitive functioning was assessed by the Mini-
Mental State Examination (MMSE) [30]. Maximum score is
30.
Assessment of Specific Cognitive Functions for the Diag-
nosis of “Probable” VaD. A variety of neuropsychological
tests, assessing specific cognitive functions, was admin-
istered to meet all the NINDS-AIREN criteria of Román and
coworkers [20]. The cognitive domains included verbal
and visual short- and long-term memory, visuospatial
attention, and executive functions.
Verbal Long-Term Memory. The eight-word test of the
Amsterdam Dementia Screening [31] assesses verbal
long-term memory, that is, direct recall (max. score: 40),
delayed recall (max. score: 8), and recognition score
(maximum score: 16).
Attention and Verbal Short-Term Memory. Digit span
forward is a subtest of the Wechsler Adult Intelligence
Scale (WAIS, Dutch version; maximum score: 14) [32] and
is meant to assess attention and short-term verbal
memory.
Table 1 Means (M), SDs, and t-tests concerning the scores on the various neuropsychological tests by
the group of patients with vascular dementia and the control group
Patients with Vascular Dementia Control Group t-Tests
M SD M SD t df P <
Verbal memory
Eight-word test
Direct recall 18.65 7.39 25.36 5.28 3.41 40 0.001**
Delayed recall 1.10 1.45 3.77 2.16 4.66 40 0.001**
Recognition 12.65 2.32 14.86 1.70 3.55 40 0.001**
Digit span forward 9.85 2.35 11.09 1.85 1.91 40 0.07
Visual memory
Face recognition 6.80 4.37 9.27 4.30 1.85 40 0.08
Picture recognition 17.65 9.92 26.09 8.52 2.97 40 0.006
Visuospatial memory
Knox Cube Test 8.22 1.67 9.23 1.15 2.25 38 0.04
Executive functions
Digit span backward 5.65 2.46 7.14 1.52 2.38 40 0.03
Rule shift cards 6.56 3.19 2.91 3.18 3.61 38 0.001**
Key search test 4.68 2.85 7.68 3.09 3.21 39 0.002**
Verbal fluency
Animals 8.60 3.86 16.55 6.22 4.92 40 0.001**
Professions 6.20 2.78 11.55 5.29 4.04 40 0.001**
** Level of significance was set at P < 0.005 to correct for multiple tests; one-tailed.
SD = standard deviations
3
Pain in “Probable” Vascular DementiaScherder et al.
444
 by guest on M
ay 8, 2016
http://painm
edicine.oxfordjournals.org/
D
ow
nloaded from
 
Visual Long-Term Memory. Face and picture recognition
are subtests of the Rivermead Behavioural Memory test
[33] assessing nonverbal long-term recognition memory
(max. score face recognition: 20; maximum score picture
recognition: 40).
Visuospatial Attention. The Knox Cube test [34] is meant
to assess visuospatial, nonverbal immediate attention,
with a maximum score of 18.
Executive Functions. Digit span backward is a subtest of
the WAIS [32] measuring verbal working memory.
Maximum score is 21. Rule Shift Card Test is a subtest of
the Behavioural Assessment of Dysexecutive Syndrome
(BADS) [35] which measures mental flexibility and impulse
control (maximum score: 21). The key search test is
another subtest of the BADS and measures planning
ability (maximum score: 16). Verbal fluency is a subtest of
the Groninger Intelligence Test (the maximum score
depends on how many words the participant is able to
mention) [36].
Vital and Gnostic Sensitivity
To assess whether the afferent pathways that mediate
sensory stimuli to the central nervous system, including
nociceptive stimuli, are intact, vital and gnostic sensitivity
were tested by a standard neurological examination.
Vital sensitivity included 1) touch, tested by touching the
forearm and the hand on different places by means of a
cotton wool; 2) temperature, assessed by applying two
plastic tubes, one filled with lukewarm water, one filled
with cold water, to the skin of the forearm and the hand in
random order; the participant was asked to indicate
whether the temperature was warm or cold; and 3) sense
of pain, tested by a pinprick, that is, applying a needle with
a sharp and a blunt side to the forearm and hand in
random order. During these tests, the participants had to
close their eyes and indicate whether they felt the sharp or
the blunt side. Gnostic sensitivity was assessed by placing
a finger of the patient in a certain position (e.g., bent or
stretched). With the eyes closed, the patient has to indi-
cate which finger has been placed in which position (e.g.,
index finger, bent).
Pain
In assessing pain, a vertical visual analogue scale and a
Faces Pain scale were administered. The vertical visual
analogue scale is in fact a pain “thermometer,” and such a
pain assessment instrument is preferred by cognitively
impaired older persons [37]. These scales have been
shown to have high intrarater and interrater reliability, as
measured by intraclass correlation coefficients (ICCs). The
ICC between the two assessments were 0.87 for the
vertical visual analogue scale, and 0.71 for the Faces Pain
Scale. The ICC between two different raters were 0.94
and 0.97, respectively [38].
The Coloured Analogue Scale (CAS) original version [39] is
a kind of vertical pain “thermometer” with a plastic slide
that can be moved upwards (“most pain”; dark red color;
score 100) and downwards (“no pain”; white/pink color;
score 0). We used the CAS original version to assess
particularly the intensity of pain.
Comprehension of the scale. First, we assessed whether
the participant understood the concept of the scale by
asking: “suppose someone, not you, has a lot of pain, in
what direction would you move the plastic slide, upwards
or downwards”? If the participant understood the concept
of the scale, we subsequently asked to indicate how much
pain they experience themselves.
Modified CAS was administered to assess the more affec-
tive aspects of pain: The label “worst pain” was replaced
by “worst suffering” (score 100) and the label “no pain” by
“no suffering” (score 0).
Comprehension of the scale. We used the same proce-
dure as with the CAS original version; however, we
replaced “has a lot of pain” by “suffers from a lot of pain.”
Faces Pain Scale [40] is a 7-point scale consisting of
seven different faces expressing no pain (one face) and
various intensities of pain (six faces). The scale is primarily
meant to assess the intensity of pain [40]. Scores range
from 0 (no pain) to 6 (most severe pain).
Comprehension of the scale. To assess whether the par-
ticipant understood the concept of the scale, we showed
all the faces to the participant and asked the participant to
indicate which face represented no pain at all and which
face represented the most severe pain. After a correct
response, we asked the participants to indicate how much
pain they experience themselves.
Procedure
As pain caused by arthrosis/arthritis and osteoporosis
might change (less or more) over a period of time, each
pain scale was administered twice, with an interval of, on
average, 2 months. For each participant, the two pain
scores were summed up (maximum score of 200 for the
CAS original and maximum score of 200 for the Modified
CAS). Subsequently the two scores of the CAS original
version and the Modified CAS were summed up into one
pain score (maximum score: 400). The tests for vital and
gnostic sensitivity, the neuropsychological tests, and the
scales for depression and anxiety were administered only
once. The order in which the tests were administered was
as follows: first, the pain scales and tests for vital and
gnostic sensitivity, followed by the neuropsychological
tests. Finally, the depression and anxiety questionnaires
were administered.
Six well-trained master students, studying Clinical Neuro-
psychology, collected the data. The administration of the
tests took place in a private room at the nursing home
(e.g., the nursing station). This ensured that participants
would not be distracted during the tests. Rest periods
were, of course, allowed, if requested by the participants.
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Data Analyses
Data were analyzed by means of Mann–Whitney U-tests,
t-tests, chi-squared tests, and analyses of variance with
mood as a covariate (ANCOVA) (SPSS version 20.0, SPSS
Inc., Chicago, IL, USA). Analgesics appeared not to cor-
relate with pain experience, as assessed by the various
pain instruments. Accordingly, analgesics were not
included as a covariate in the data analyses. Concerning
cognition, level of significance was set at P < 0.005 to
control for multiple tests. For the remaining dependent
variables, level of significance was set at P < 0.05, one-
tailed. Effect sizes η2 were small, 0.1; moderate, 0.6; and
large, 0.14 [41].
Results
Demographics
The mean age of the VaD group (M = 80.85, standard
deviation [SD] = 4.91) differed significantly from the age of
the control group (M = 85.59, SD = 5.60) (t[40] = 2.90,
P = 0.006). Gender did not differ significantly between
both groups (χ2 = 0.81, df = 2, P = 0.37). Furthermore, the
level of education of the VaD group (median = 3; IQR: 2)
and the control group (median 4; IQR: 3) did not differ
significantly (Mann–Whitney U: Z = 1.36, P = 0.19).
Comorbidity
The presence/absence of these disorders, expressed in
percentages, did not differ significantly between both
groups (results from data analyses by chi-squared are not
shown). Consequently, the percentage of total comor-
bidity did not differ between both groups (χ2 = 15.09,
df = 12, P = 0.24).
Analgesics
Patients with VaD and participants of the control group did
not differ significantly concerning the use of acetamino-
phen (paracetamol [acetaminophen]), NSAIDs, and mor-
phine (see Table 2). Similarly, concerning the overall use of
analgesics, both groups did not show a significant
difference.
Mood
Both groups did not differ significantly concerning depres-
sion and anxiety (see Table 3 for means, SDs, and t-tests).
Global Cognitive Functioning
As expected, the MMSE scores differed significantly
between the VaD group (M = 19.50, range: 11–24) and
the control group (M = 26.95, range: 25–29) (t[40] = 9.02,
P < 0.001).
Specific Cognitive Functions
Data analyses by means of t-tests show that, compared
with the control group, patients with VaD perform signifi-
cantly worse on tests appealing to verbal memory (eight-
word test) and executive functions (rule shift cards, key
search test, and verbal fluency). Furthermore, the differ-
ence between both groups concerning picture recognition
showed a trend; the mean score on Picture recognition of
patients with VaD was lower than that of the control group.
For means, SDs, and t-tests, see Table 1.
Vital and Gnostic Sensitivity
Vital Sensitivity
Temperature did not differ significantly between both
groups (χ2 = 0.01, df = 1, P = 0.95). Similar findings were
observed concerning sense of pain (χ2 = 1.67, df = 1,
P = 0.20). The participants of both groups correctly
reported each time they were touched by a cotton wool.
Gnostic Sensitivity
No significant difference was observed between both
groups (χ2 = 0.31, df = 1, P = 0.58).
Pain
CAS Original
An analysis of variance with anxiety/depression as a
covariate showed that the VaD patients (M = 103.75;
SD = 59.41) did not differ significantly from the control
group (M = 74.14; SD = 43.20) (F[1,29] = 1.56, P = 0.11,
η2 = 0.05).
CAS Modified
An analysis of variance with anxiety/depression as a
covariate showed that the VaD patients had a significantly
higher mean pain score (M = 102.32; SD = 53.42) than
the control group (M = 59.17; SD = 38.75) (F[1,29] = 5.62,
P = 0.01, η2 = 0.16).
Table 2 Percentages and chi-squared tests
relating to the use of paracetamol, NSAIDs, and
morphine in the group of patients with vascular
dementia and in the control group
Analgesics
Patients with
Vascular
Dementia %
Control
Group %
Chi-Squared Tests
χ2 df P
Paracetamol 18.2 31.6 0.26 1 0.61
NSAIDs 27.3 10.5 1.41 1 0.24
Morphine 9.1 10.5 0.02 1 1.00
Overall use 45.5 42.1 0.08 2 0.96
NSAID = non-steroidal anti-inflammatory drug.
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Faces Pain Scale
The VaD group (M = 4.00; SD = 2.30) and the control
group (M = 3.11; SD = 2.70) did not show a significant
difference concerning the Faces Pain Scale
(F[1,27] = 0.94, P = 0.17, η2 = 0.04).
Discussion
Key Finding
To our knowledge, this is the first study to examine expe-
rienced pain in patients with “probable” VaD. It is difficult
to make this diagnosis in nursing homes as brain imaging
is not a standard procedure in these institutions. However,
this affects millions of people with dementia throughout
the world. The key finding in the present study is that
patients in a mild to moderate stage of “probable” VaD
report experiencing significantly more chronic pain than do
older individuals without dementia. A large effect size was
involved. This finding confirms the results of our previous
study, which focused on patients with “possible” VaD [16].
Chronic Pain in VaD
The hypothesis that an increase in pain in patients with
“probable” VaD who are also suffering from conditions
such as arthrosis/arthritis or osteoporosis that might be
caused by white matter damage (due to deafferentiation)
is only partly supported by the present study. White matter
lesions were explicitly reported in about half of the
patients. On the other hand, in those with a single lesion,
hypertension was observed, and a close relationship
between hypertension and white matter lesions is well
known [42]. The clinical relevance of the finding reported
here is that because patients with white matter lesions
exhibit a combination of increased pain and decreased
cognition, they are at risk of being undertreated for pain
[43]. In the present study, there is only indirect support for
the latter suggestion. There were no reliable details about
the dosages of analgesics given, but although the number
of participants for whom analgesics were prescribed on an
“only if needed” basis was the same in both groups, the
patients with “probable” VaD reported more severe pain.
We argue that the presence of white matter lesions in AD
[44] and FTD [45] should alert attending physicians to the
fact that their patients may be experiencing increased pain
and that the doses of pain medication should be adjusted
accordingly.
Central Neuropathic Pain
The rationale for testing vital and gnostic sensitivity was
that VaD patients exhibit decreased glucose metabolism
in regions such as the thalamus [46]. The thalamus is
known to transmit somatosensory information to the
cortex [47], and any dysfunction in this process can cause
central neuropathic pain [48]. This pain, in turn, might be
reflected by either hypoalgesia or hyperalgesia to a pin-
prick (sense of pain), for example [49]. However, there was
no significant difference between these groups in terms of
their responses to the tests for temperature sensitivity,
sense of pain, and gnostic sensitivity. This part of the
study was affected by the limitation that vital and gnostic
sensory testing was restricted to the participants’ fore-
arms, rather than using several different parts of the body.
It is essential for the attending physician to know whether
or not their patient’s pain is of central origin as this type of
pain does not respond to acetaminophen. In such cases,
antidepressants and antiepileptic drugs might be more
effective [50].
Diagnosis of “Probable” Subcortical Ischaemic VaD
Our cognitive data meet the NINDS-AIRENS criteria on
which the diagnosis of “probable” VaD is based [20], that
is, a cognitive decline in episodic memory (eight-word test)
and in two or more other cognitive domains, that is, visual
memory (picture recognition) and executive functions (rule
shift cards, key search test, and verbal fluency). Although
a decline in executive functioning supports a diagnosis of
“probable” VaD [51,52], there is some evidence to suggest
that the impairment in verbal fluency observed here might
instead be an indication of AD. Indeed, in some studies
comparing VaD patients with AD patients, the latter
achieved poorer verbal fluency scores than VaD patients
[53]. However, the verbal fluency scores of VaD patients
were still significantly lower than those of the control group
[53], which corresponds to our own findings. Yet AD
patients were not always outperformed by VaD patients in
terms of verbal fluency scores. In one study, they per-
formed this task better than VaD patients, although the
difference involved was not significant [54].
Table 3 Means (M), SDs, and t-tests concerning the depression and anxiety scores of the group of
patients with vascular dementia and the control group
Patients with Vascular Dementia Control Group t-Tests
M SD M SD t df P
GDS 10.06 6.42 8.23 5.42 0.98 38 0.34
SCL-90 anxiety 15.47 7.20 13.71 5.06 0.90 38 0.37
SCL-90 depression 25.53 9.78 24.43 7.89 0.39 38 0.70
GDS = Geriatric Depression Scale; SCL-90 = Symptom Check List-90; SD = standard deviation.
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The diagnosis of VaD is further supported by the fact that
the patients in the present study scored higher on the
recognition test than on the delayed recall subtest of the
eight-word test (see Table 1). The latter requires the active
retrieval of information from a memory store, a process
that has been found to be particularly severely impaired in
VaD patients [21].
On the other hand, the NINDS-AIREN criteria are known
to exhibit relatively low sensitivity. Gold et al. [55] report a
sensitivity of 58% and a specificity of 80%. However, in
another study, the psychometric qualities of NINDS-
AIREN criteria were compared with three other diagnostic
“schemes,” that is, the ADDTC criteria (AD Diagnostic and
Treatment Center’s criteria for ischemic vascular demen-
tia), Bennett’s criteria for Binswanger’s disease, and the
ICD-10 criteria for VaD [56]. It was concluded that a diag-
nosis of VaD made by using one of these schemes was
not always confirmed by the others [56]. According to the
authors, the heterogeneous nature of VaD tends to under-
mine the usefulness of these schemes. Instead, they
emphasize the diagnostic value of factors such as these
patients’ neuropsychological functioning (e.g., a more
severe decline in executive functions compared with rec-
ognition memory).
Additional Limitations
One of the inclusion criteria was that VaD had to be
confirmed by a neurologist who performed brain imaging.
However, a visit to a neurologist who performs brain
imaging is not a standard procedure in nursing homes in
the Netherlands. A second criterion was that the patient’s
medical status had to indicate the presence of arthrosis/
arthritis or osteoporosis. The third criterion was that the
individual had to be willing to participate. Together, these
three inclusion criteria greatly limited the number of par-
ticipants that were able to meet the inclusion requirements
for the present study. As a result, it took approximately 6
years to complete the study. Nevertheless, it would be
feasible to carry out a large-scale study, particularly if the
patients in question were at a relatively early stage of the
disease. Such patients still live at home and are referred to
a university hospital for a one-day screening that includes
CT/MRI, a neuropsychological examination, and a blood
test. A large-scale study would also address a second
limitation, that is, VaD has a heterogeneous etiology, so it
would have been useful to subdivide the groups and
analyze the data per subgroup. However, given the limited
number of participants in the present study, there would
be too few individuals in each subgroup to carry out
subgroup analyses of this kind. A third limitation is that we
assume that if the patient understands the concept of a
pain scale, then their understanding of the concept of
“pain” (in the sense of somatic pain) is also intact.
However, it is possible that the patient is suffering from
grief (due to the loss of a child, for example) and that they
translate this as “pain.” A fourth limitation is the use of the
Geriatric Depression Scale as a means of assessing
depression in a group of patients with dementia. The
validity of this instrument in this specific population has
been questioned [57], at least for those with an MMSE
score below 14. A final limitation is that we have
no information on the subjects’ medication use during
the 24 hours immediately preceding the pain assessment
procedure.
Clinical and Research Implications
As VaD patients appear to experience more pain than
controls, it is essential for prescribers to be aware of the
presence of this neuropathology if these patients are to
receive adequate pain treatment. Larger-scale brain
imaging studies, confirming the present findings, will
reduce the risk that millions of patients suffering from VaD
will be undertreated for pain.
Finally, given the number of patients involved, together
with other limitations, it should be noted that these find-
ings are preliminary in nature and that they need to be
validated by future studies.
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